Market Overview

Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results

Share:
Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results

Cara Therapeutics Inc (NASDAQ: CARA) got some love from Wall Street on Tuesday, with one analyst projecting significant upside for the stock based the outlook for its leading drug candidate.

The Analyst

Bank of America Merrill Lynch analyst Jason Gerberry initiated coverage of Cara with a Neutral rating and set a $19 price target.

The Thesis

The $19 price target is based on a discounted cash flow analysis of Cara's leading asset IV Korsuva (CR845) in Phase 3 studies for pruritus associated with end-stage renal disease hemodialysis treatment, Gerberry said in the Tuesday initiation note.

Data readouts coming in 2019 make the stock a highly binary trade in the near-term, with large potential upside and downside, the analyst said.

The stock's key catalysts are Phase 3 topline results for IV Korsuva in ESRD-HD in the mid- and back-half of 2019 and Phase 2 topline data for oral Korsuva in CKD3-5, likely in the second half of the year, Gerberry said. 

The stock is pricing in roughly a 65-percent probability of a favorable outcome for IV Korsuva, he said. 

The drug has both positives and negatives ahead of Phase 3 data, the analyst said. Phase II efficacy and safety readouts were positive, and Gerberry said the drug should benefit from a commercial partnership with VIFOR.

Negatives include Phase 2 data variability across dose arms and unclear reimbursement mechanisms on the distribution front, he said. 

BofA projects peak IV Korsuva sales of $530 million, which includes assumptions of acceptable reimbursement rates and 45-percent peak penetration rates in ESRD-HD patients with moderate-to-severe chronic itch, or about 40 percent of the patient population.

Price Action

Cara Therapeutics shares were up 1.19 percent at $15.31 at the time of publication Tuesday. 

Related Links:

This Biotech ETF Is Soaring, But A Bearish Friend Lures Traders

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Latest Ratings for CARA

DateFirmActionFromTo
Jul 2019MaintainsOverweight
May 2019MaintainsBuy
May 2019MaintainsBuy

View More Analyst Ratings for CARA
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill Lynch Jason GerberryAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (CARA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MSGNDowngrades
HUBBInitiates Coverage On160.0
CTREUpgrades25.0
GLNGMaintains27.0
SEMaintains45.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Today's Pickup: Robotic Delivery, FedEx Furniture, Israeli Blockchain

Volvo Finding Early Success With Subscription-Based Car Model